Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Acasti Pharma Inc

Healthcare US ACST

3.28USD
-0.09(2.67%)

Last update at 2024-11-20T14:30:00Z

Day Range

3.013.49
LowHigh

52 Week Range

1.723.84
LowHigh

Fundamentals

  • Previous Close 3.37
  • Market Cap24.72M
  • Volume61071
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.21100M
  • Revenue TTM0.12M
  • Revenue Per Share TTM0.005
  • Gross Profit TTM 0.12M
  • Diluted EPS TTM-5.49

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -51.97100M -10.46700M -19.67800M -25.51300M -38.62043M
Minority interest - - - - 0.00000M
Net income -42.42900M -9.81900M -19.67800M -25.76000M -43.86159M
Selling general administrative 8.08M 9.26M 5.51M 5.80M 4.24M
Selling and marketing expenses 0.14M 0.52M 1.14M 2.67M -
Gross profit -52.15500M -15.58900M 0.12M - 0.00000M
Reconciled depreciation 0.12M 0.00000M 0.92M 2.32M 2.12M
Ebit 15.72M -15.58900M -10.71600M -24.43800M -33.71405M
Ebitda 15.85M -19.98900M -9.94900M -21.82800M -30.98862M
Depreciation and amortization 0.12M -4.40000M 0.77M 2.61M 2.73M
Non operating income net other - - - - 0.00000M
Operating income 15.72M -15.58900M -10.71600M -24.43800M -33.71405M
Other operating expenses 18.25M 15.34M 10.91M 24.44M 32.97M
Interest expense 67.69M 0.22M 0.16M 0.25M 0.27M
Tax provision -9.54200M -0.64800M - - 0.00000M
Interest income 0.25M 0.08M 0.11M 0.34M 0.36M
Net interest income 0.25M 0.22M -0.15700M 0.04M -0.40668M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -9.54200M -0.64800M 8.80M 0.25M 5.24M
Total revenue 0.00000M 0.01M 0.20M 0.00000M 0.00000M
Total operating expenses 18.25M 15.34M 10.84M 24.44M 32.97M
Cost of revenue 52.16M 15.59M 0.08M - 0.00000M
Total other income expense net -67.69400M 5.12M -8.96200M -1.07500M -4.90638M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -42.42900M -9.81900M -19.67800M -25.51300M -38.62043M
Net income applicable to common shares - -9.81900M -19.67800M -25.51300M -39.36600M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 79.12M 128.62M 62.46M 22.85M 36.30M
Intangible assets 41.13M 69.81M - 4.24M 5.80M
Earning assets - - - - -
Other current assets 0.60M 1.32M 1.11M 0.20M 0.05M
Total liab 11.17M 20.35M 6.80M 9.86M 25.85M
Total stockholder equity 67.95M 108.27M 55.66M 12.99M 10.46M
Deferred long term liab - - - - 0.00000M
Other current liab 3.34M 1.48M 1.38M 5.61M 9.26M
Common stock 258.29M 257.99M 197.19M 137.42M 96.85M
Capital stock 258.29M 257.99M 197.19M 137.42M 96.85M
Retained earnings -198.26600M -155.83700M -146.01800M -126.34000M -92.82879M
Other liab - 16.90M 5.22M 2.39M 12.18M
Good will 8.14M 12.96M - - 0.00000M
Other assets - - - 0.47M 0.42M
Cash 27.88M 30.34M 50.94M 14.24M 16.87M
Cash and equivalents - - - - -
Total current liabilities 3.41M 3.26M 1.58M 7.39M 13.67M
Current deferred revenue -1.24200M - - - -
Net debt -27.39000M -30.04400M -50.85600M -14.09300M -15.50629M
Short term debt 0.07M 0.10M 0.09M 0.08M 1.36M
Short long term debt - - - - 1.36M
Short long term debt total 0.48M 0.29M 0.09M 0.15M 1.36M
Other stockholder equity 13.96M 12.15M 10.82M 9.80M 7.32M
Property plant equipment - 0.32M 0.09M 2.06M 2.11M
Total current assets 29.29M 45.53M 62.37M 16.08M 27.96M
Long term investments - - - 0.00000M 0.02M
Net tangible assets - 25.50M 55.66M 8.75M 4.66M
Short term investments 0.01M 13.32M 9.79M 0.00500M 8.89M
Net receivables 0.80M 0.55M 0.53M 0.55M 1.19M
Long term debt - - - - 0.00000M
Inventory - - - 1.10M 0.97M
Accounts payable 1.24M 1.68M 0.12M 1.71M 3.04M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income -6.03800M -6.03700M -6.33300M -7.88700M -0.88826M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - 197.19M - 96.85M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 0.10M - - 0.47M 0.42M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 49.83M 83.09M 0.09M 6.77M 8.34M
Capital lease obligations 0.48M 0.29M 0.09M 0.15M 0.00000M
Long term debt total - - - - 0.00000M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments 13.15M -3.52200M -9.78900M 8.14M -8.90800M
Change to liabilities - -2.38800M -6.70100M -3.38900M 7.44M
Total cashflows from investing activities - -3.52200M -9.85800M 8.14M -9.44200M
Net borrowings - - - -1.55600M -1.55600M
Total cash from financing activities 0.30M 0.00000M 59.49M 13.18M 44.08M
Change to operating activities - -2.78600M 0.70M -0.40300M -0.63600M
Net income -42.42900M -9.81900M -19.67800M -25.51300M -38.62043M
Change in cash -2.46400M -20.60300M 36.70M -2.63100M 10.71M
Begin period cash flow 30.34M 50.94M 14.24M 16.87M 6.16M
End period cash flow 27.88M 30.34M 50.94M 14.24M 16.87M
Total cash from operating activities -15.91300M -17.23400M -14.31900M -22.94400M -24.32295M
Issuance of capital stock 0.30M 0.00000M 59.33M 6.98M 43.36M
Depreciation 0.12M 0.00000M 0.92M 2.32M 2.12M
Other cashflows from investing activities - - - 8.46M -8.90800M
Dividends paid - - - - 0.00000M
Change to inventory - - - - 0.00000M
Change to account receivables - -0.01800M 0.06M 0.58M -0.62000M
Sale purchase of stock - - - 14.73M 45.69M
Other cashflows from financing activities 13.15M -3.52200M 0.16M 7.75M 0.73M
Change to netincome - -4.62900M 10.12M 3.46M 6.06M
Capital expenditures 0.02M 0.00000M 0.07M 0.32M 0.52M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital 0.18M -2.78600M -5.94600M -3.21100M 6.06M
Stock based compensation 1.81M 1.34M 1.17M 1.95M 0.78M
Other non cash items 33.94M -5.31800M 0.26M 0.14M 4.91M
Free cash flow -15.93000M -17.23400M -14.38800M -23.26300M -24.84721M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ACST
Acasti Pharma Inc		 -0.09 2.67% 3.28 - - 208.39 0.49 5.50 -0.5644
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Acasti Pharma Inc

3009 boulevard de la Concorde East, Laval, QC, Canada, H7E 2B5

Key Executives

Name Title Year Born
Ms. Janelle D'Alvise Pres, CEO, Corp. Sec. & Director 1955
Dr. Pierre Lemieux M.D., Ph.D. Co-Founder, COO & Chief Scientific Officer 1965
Mr. Brian D. Ford CPA, CA Chief Financial Officer 1959
Dr. George Kottayil Chief Operating Officer of US 1963
Mr. Prashant Kohli Chief Commercial Officer NA
Dr. Yves Lachance Ph.D. VP of Quality & Compliance NA
Ms. Christine Pelletier Sr. Director of HR NA
Mr. Prashant Kohli CEO & Director 1972
Mr. Robert J. DelAversano CPA Principal Financial & Accounting Officer 1972
Dr. R. Loch MacDonald M.D., Ph.D. Member of Scientific Advisory Board & Chief Medical Officer 1962

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.